Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers

Next Previous
Trial Profile

A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raludotatug deruxtecan (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms REJOICE-GI01
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 12 Jun 2025 Planned End Date changed from 6 May 2029 to 4 Jan 2029.
  • 04 Apr 2025 Status changed from not yet recruiting to recruiting.
  • 11 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top